4.7 Article

Characterisation of endogenous A2A and A2B receptor-mediated cyclic AMP responses in HEK 293 cells using the GloSensor™ biosensor: Evidence for an allosteric mechanism of action for the A2B-selective antagonist PSB 603

期刊

BIOCHEMICAL PHARMACOLOGY
卷 147, 期 -, 页码 55-66

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2017.10.013

关键词

Adenosine receptor; Cyclic AMP; Kinetics; Allosterism; PSB 603; A(2B) receptor

资金

  1. Medical Research Council [G0800006]
  2. National Health and Medical Research Council (NHRMC)
  3. Medical Research Council [G0800006] Funding Source: researchfish
  4. MRC [G0800006] Funding Source: UKRI

向作者/读者索取更多资源

Endogenous adenosine A(2B) receptors (A(2B)AR) mediate cAMP accumulation in HEK 293 cells. Here we have used a biosensor to investigate the mechanism of action of the A(2B)AR antagonist PSB 603 in HEK 293 cells. The A(2A) agonist CGS 21680 elicited a small response in these cells (circa 20% of that obtained with NECA), suggesting that they also contain a small population of A(2A) receptors. The responses to NECA and adenosine were antagonised by PSB 603, but not by the selective A(2A)AR antagonist SCH 58261. In contrast, CGS 21680 responses were not antagonised by high concentrations of PSB 603, but were sensitive to inhibition by SCH 58261. Analysis of the effect of increasing concentrations of PSB 603 on the response to NECA indicated a non-competitive mode of action yielding a marked reduction in the NECA E-MAX with no significant effect on EC50 values. Kinetics analysis of the effect of PSB 603 on the A(2B)AR-mediated NECA responses confirmed a saturable effect that was consistent with an allosteric mode of antagonism. The possibility that PSB 603 acts as a negative allosteric modulator of A(2B)AR suggests new approaches to the development of therapeutic agents to treat conditions where adenosine levels are high. (C) 2017 The Author(s). Published by Elsevier Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据